perinatal asphyxia, neuroprotection, allopurinol, newborn, oxidative stress
Conditions
Interventions
Randomized, double blind controlled allopuirnol (500mg iv) or placebo as soon as fetal hypoxia is imminent
Sponsors
Prof dr. F. van Bel
Eligibility
Inclusion criteria
Inclusion criteria: 1. Gestational age of 36 weeks or more, determined by maternal dates and/or Ballard score. 2. Objective fetal hypoxia registered by: - Abnormalities on STAN S21 fetal electrocardiography monitor (Neoventa Medical, Gothenborg, Sweden). A fetal scalp electrode is allocated to the parturient for continuous internal cardiotocographic recordings combined with the computer for fetal heart monitor for ST analysis of the fetal electrocardiogram signals, which are stored automatically in digital form OR - non-reassuring CTG - Fetal blood sampling: pH<7.20 3. Informed consent given by patient.
Exclusion criteria
Exclusion criteria: 1. Congenital, chromosomal or syndromal malformations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The brain damage marker S100B and the severity of oxidative stress measured in umbilical cord blood and neonatal blood (isoprostane, neuroprostane, non protein bound iron). | — |
Secondary
| Measure | Time frame |
|---|---|
| Neonatal mortality and serious composite morbidity. | — |
Contacts
Public ContactM.J.N.L. Benders
Universitair Medisch Centrum Utrecht Lokatie Wilhelmina Kinderziekenhuis (WKZ) KE 04.123.1 Postbus 85090
Outcome results
None listed